Amphastar Shares Surge Following Impressive Quarterly Earnings Report

Amphastar Pharmaceuticals witnessed a significant uptick in its stock performance after releasing quarterly results that substantially outpaced market projections. The company’s latest financial metrics have injected fresh momentum into its recent rally, demonstrating stronger-than-anticipated operational performance.

For the third quarter of 2025, Amphastar reported net revenue reaching $191.8 million, comfortably surpassing the consensus estimate of $184.5 million among market analysts. The company’s adjusted net profit showed remarkable strength, climbing to $44.7 million. This translated to earnings of $0.93 per diluted share, exceeding the $0.83 per share that financial experts had projected.

The robust quarterly performance received substantial support from continued commercial success of two key products: Baqsimi and Primatene Mist. These established pharmaceutical offerings Read more...